Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Gains from Investment Securities (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Gains from Investment Securities for 14 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 75.04% year-over-year to $6.5 million, compared with a TTM value of $6.5 million through Dec 2025, down 75.04%, and an annual FY2025 reading of $6.5 million, down 75.04% over the prior year.
  • Gains from Investment Securities was $6.5 million for Q4 2025 at Heron Therapeutics, down from $28.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $29.4 million in Q1 2024 and bottomed at $33000.0 in Q4 2023.
  • Average Gains from Investment Securities over 5 years is $13.7 million, with a median of $12.4 million recorded in 2021.
  • The sharpest move saw Gains from Investment Securities tumbled 96.15% in 2021, then surged 78936.36% in 2024.
  • Year by year, Gains from Investment Securities stood at $18.9 million in 2021, then tumbled by 79.64% to $3.9 million in 2022, then tumbled by 99.14% to $33000.0 in 2023, then soared by 78936.36% to $26.1 million in 2024, then tumbled by 75.04% to $6.5 million in 2025.
  • Business Quant data shows Gains from Investment Securities for HRTX at $6.5 million in Q4 2025, $28.9 million in Q3 2025, and $26.1 million in Q1 2025.